NCT01929317 - A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 28, 2013

Primary Completion Date

September 16, 2014

Study Completion Date

June 9, 2015

Conditions

Parkinson Disease

Interventions

DRUG

Ropinirole CR 2mg tablet

Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.

DRUG

Ropinirole CR 8mg tablet

Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.

DRUG

Ropinirole CR matching Placebo tablet

Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.

Trial Locations (17)

466-8560

GSK Investigational Site, Aichi

010-0874

GSK Investigational Site, Akita

030-8553

GSK Investigational Site, Aomori

070-8530

GSK Investigational Site, Hokkaido

070-8644

GSK Investigational Site, Hokkaido

672-8043

GSK Investigational Site, Hyōgo

674-0081

GSK Investigational Site, Hyōgo

760-0027

GSK Investigational Site, Kagawa

252-0392

GSK Investigational Site, Kanagawa

600-8811

GSK Investigational Site, Kyoto

020-0878

GSK Investigational Site, Numakunai

025-0075

GSK Investigational Site, Numakunai

703-8265

GSK Investigational Site, Okayama

530-8480

GSK Investigational Site, Osaka

578-8588

GSK Investigational Site, Osaka

416-0955

GSK Investigational Site, Shizuoka

433-8125

GSK Investigational Site, Shizuoka